Celea Therapeutics, a PureTech Health spinout, secured $180 million to support a pivotal Phase 3 program for idiopathic pulmonary fibrosis (IPF) using deupirfenidone, an oral small-molecule candidate. The study is designed as a head-to-head comparison against a standard-of-care IPF drug, positioning the company to directly test relative efficacy rather than relying on placebo-controlled outcomes. The financing is explicitly tied to the pivotal test, indicating an accelerated push toward late-stage evidence generation and potential registration-level data. For IPF investors, the structure of the trial matters because cross-trial comparisons can obscure signals, while head-to-head designs can sharpen differentiation on endpoints that guide clinical adoption. While specific endpoint definitions and expected timelines were not included in the provided excerpt, the funding amount and the Phase 3 intent signal that deupirfenidone is moving into the competitive phase of IPF therapeutics, where payer and guideline decisions increasingly depend on comparative results. For stakeholders watching PureTech’s portfolio transitions, the funding also underscores how spinouts are leveraging capital-intensive late-stage studies to compete on efficacy and safety at scale.